Home / Recalls / Central Admixture Pharmacy Services, Inc. / D-0955-2023

D-0955-2023 Class II Terminated

Recalled by Central Admixture Pharmacy Services, Inc. — Phoenix, AZ

Recall Details

Product Type
Drugs
Report Date
August 9, 2023
Initiation Date
July 14, 2023
Termination Date
March 28, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
15,304 bags

Product Description

vancomycin 1.25 g/250 mL added to 0.9% Sodium Chloride, 5 mg/mL, IV Bag, Rx only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Phoenix, AZ 85043, NDC: 72196-6074-1

Reason for Recall

Lack of assurance of sterility. Validation data for decontamination cycles is lacking.

Distribution Pattern

Nationwide in the USA

Code Information

Lot: 36-254431, Exp. 9/5/2023; 36-255125, 36-255126, 36-255127, Exp. 9/6/2023; 36-248083 Exp. 8/10/2023; 36-238973, 36-238980, Exp. 7/10/2023; 36-239520, Exp. 7/12/2023; 36-240087, Exp. 7/13/2023; 36-248979, 36-248980, 36-248981, Exp. 8/16/2023; 36-240760, 36-240761, 36-240762, Exp. 7/17/2023; 36-240837, 36-240838, Exp. 7/18/2023; 36-241131, 36-241132, Exp. 7/19/2023; 36-241436, Exp. 7/20/2023; 36-251065, Exp. 8/24/2023; 36-241980, Exp. 7/24/2023; 36-242707, Exp. 7/26/2023; 36-243153, 36-243155, 36-243156, Exp. 7/27/2023; 36-252188, 36-252189, 36-252191, 36-252192, 36-252198, 36-252201, Exp. 8/31/2023; 36-243951, Exp. 7/31/2023.

Other recalls by Central Admixture Pharmacy Services, Inc.

  • D-0272-2025 Class I — PHENYLephrine added to 0.9% sodium chloride, 40 mg/250 mL* (160 mcg/mL), Rx Only (February 20, 2025)
  • D-0007-2024 Class II — PHENYLephrine in 0.9% sodium chloride, 1,000 mcg/10 mL, (100 mcg/mL), 10 mL syri (September 21, 2023)
  • D-0009-2024 Class II — fentaNYL in 0.9% sodium chloride, 10 mcg/1 mL, (10 mcg/mL), 3 mL Syringe, Rx onl (September 21, 2023)
  • D-0016-2024 Class II — fentaNYL 2 mcg/mL and bupivacaine 0.0625% PF in 0.9% sodium chloride, Total Volu (September 21, 2023)
  • D-0020-2024 Class II — fentaNYL, 250 mcg/5 mL, (50 mcg/mL), 5 mL Syringe, Rx only, Repackaged by CAPS I (September 21, 2023)
  • D-0013-2024 Class II — fentaNYL in 0.9% sodium chloride, 2,500 mcg/250 mL, (10 mcg/mL), 250 mL bag, Rx (September 21, 2023)
  • D-0028-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 10 mg/50 mL, (0.2 mg/mL), 50 mL Syringe, (September 21, 2023)
  • D-0018-2024 Class II — midazolam in dextrose 5%, 50 mg/50 mL, (1 mg/mL), 50 mL Syringe, Rx only, Centra (September 21, 2023)
  • D-0027-2024 Class II — HYDROmorphone in 0.9% sodium chloride, 6 mg/30 mL, (0.2 mg/mL), 30 mL Syringe, R (September 21, 2023)
  • D-0025-2024 Class II — fentaNYL, 1,250 mcg/25 mL, (50 mcg/mL), 30 mL Syringe, Rx only, Central Admixtur (September 21, 2023)